SCHEMBL379757

SCHEMBL379757

Cc1ccc(-c2csc3ccnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.47
CDK8 P49336 1/20 0.47
ESR1 P03372 3/20 0.47
KDR P35968 6/20 0.47
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.45
TNF P01375 1/20 0.43
MAPK1 P28482 1/20 0.43
NOD1 Q9Y239 1/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
UTS2R Q9UKP6 1/20 0.43
NOS2 P35228 1/20 0.42
HTT P42858 1/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
PIM1 P11309 1/20 0.41
DYRK1A Q13627 1/20 0.41
DYRK2 Q92630 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379865 0.91 ESR1 (0.55) CCNCCDK8ESR1KDRHPGD
SCHEMBL379602 0.88 PDE11A (0.47) CCNCCDK8ESR1KDRTP53
SCHEMBL4946829 0.87 PDE11A (0.49) CCNCCDK8ESR1KDRTP53
SCHEMBL379640 0.83 MAPT (0.53) ESR1KDRHPGDNPSR1TP53
SCHEMBL379874 0.81 CCNC (0.47) CCNCCDK8ESR1KDRHPGD
SCHEMBL379643 0.80 CYP1A2 (0.58) CCNCCDK8HPGDTP53MAPK1
SCHEMBL379662 0.80 CCNC (0.49) CCNCCDK8ESR1KDRHPGD
SCHEMBL379876 0.80 BTK (0.47) CCNCCDK8ESR1KDRHPGD
SCHEMBL379896 0.79 CLK4 (0.59) KDRHPGDTP53MAPK1DYRK1A
SCHEMBL379504 0.79 TNF (0.47) CCNCCDK8ESR1KDRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 CCNC 2358/4885CDK8 1639/4885ESR1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.